SG11202112354SA - Crystal form of pyridone derivative, and preparation method and use thereof - Google Patents
Crystal form of pyridone derivative, and preparation method and use thereofInfo
- Publication number
- SG11202112354SA SG11202112354SA SG11202112354SA SG11202112354SA SG11202112354SA SG 11202112354S A SG11202112354S A SG 11202112354SA SG 11202112354S A SG11202112354S A SG 11202112354SA SG 11202112354S A SG11202112354S A SG 11202112354SA SG 11202112354S A SG11202112354S A SG 11202112354SA
- Authority
- SG
- Singapore
- Prior art keywords
- preparation
- crystal form
- pyridone derivative
- pyridone
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910381020.0A CN111909174B (zh) | 2019-05-08 | 2019-05-08 | 吡啶酮衍生物的晶型及制备方法和应用 |
| PCT/CN2019/115641 WO2020224208A1 (fr) | 2019-05-08 | 2019-11-05 | Forme cristalline d'un dérivé de pyridone, procédé de préparation correspondant et utilisation associée |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112354SA true SG11202112354SA (en) | 2021-12-30 |
Family
ID=73050743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112354SA SG11202112354SA (en) | 2019-05-08 | 2019-11-05 | Crystal form of pyridone derivative, and preparation method and use thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230144122A1 (fr) |
| EP (1) | EP3967697A4 (fr) |
| CN (2) | CN111909174B (fr) |
| AU (1) | AU2019444375B2 (fr) |
| CA (1) | CA3139343A1 (fr) |
| SG (1) | SG11202112354SA (fr) |
| WO (1) | WO2020224208A1 (fr) |
| ZA (1) | ZA202108765B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115385932A (zh) * | 2021-05-22 | 2022-11-25 | 江西彩石医药科技有限公司 | 吡啶酮衍生物的中间体及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2444400T (lt) * | 2009-06-15 | 2018-06-11 | Shionogi & Co., Ltd. | Pakeistasis policiklinis karbamoilpiridono darinys |
| AU2011307087B2 (en) * | 2010-09-24 | 2016-11-10 | Shionogi & Co., Ltd. | Substituted polycyclic carbamoyl pyridone derivative prodrug |
| MX2017013809A (es) * | 2015-04-28 | 2018-03-15 | Shionogi & Co | Derivados de piridona policiclica sustituida y profarmaco de los mismos. |
| KR20190014086A (ko) * | 2016-08-10 | 2019-02-11 | 시오노기세야쿠 가부시키가이샤 | 치환된 다환성 피리돈 유도체 및 그의 프로드러그를 함유하는 의약 조성물 |
| WO2019141179A1 (fr) * | 2018-01-17 | 2019-07-25 | 银杏树药业(苏州)有限公司 | Dérivé de pyridone, composition de celui-ci et son utilisation en tant que médicament contre la grippe |
-
2019
- 2019-05-08 CN CN201910381020.0A patent/CN111909174B/zh active Active
- 2019-11-05 AU AU2019444375A patent/AU2019444375B2/en active Active
- 2019-11-05 WO PCT/CN2019/115641 patent/WO2020224208A1/fr unknown
- 2019-11-05 SG SG11202112354SA patent/SG11202112354SA/en unknown
- 2019-11-05 CN CN201980005140.9A patent/CN111670191B/zh active Active
- 2019-11-05 CA CA3139343A patent/CA3139343A1/fr active Pending
- 2019-11-05 US US17/595,013 patent/US20230144122A1/en active Pending
- 2019-11-05 EP EP19928278.1A patent/EP3967697A4/fr active Pending
-
2021
- 2021-11-08 ZA ZA2021/08765A patent/ZA202108765B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3139343A1 (fr) | 2020-11-12 |
| CN111670191B (zh) | 2021-07-13 |
| CN111909174B (zh) | 2022-01-21 |
| WO2020224208A1 (fr) | 2020-11-12 |
| EP3967697A1 (fr) | 2022-03-16 |
| CN111909174A (zh) | 2020-11-10 |
| CN111670191A (zh) | 2020-09-15 |
| EP3967697A4 (fr) | 2023-07-05 |
| AU2019444375A1 (en) | 2021-12-02 |
| AU2019444375B2 (en) | 2023-04-20 |
| US20230144122A1 (en) | 2023-05-11 |
| ZA202108765B (en) | 2023-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291467A (en) | Compressed pyridone compound, method for its preparation and use | |
| EP3470400A4 (fr) | Forme cristalline de l'ozanimod, forme cristalline de son hydrochloride et son procédé de préparation | |
| EP3287444A4 (fr) | Nouvelle forme cristalline de sel de méthanesulfonate de lenvatinib et son procédé de préparation | |
| EP3682884A4 (fr) | Forme cristalline de gsk1278863 et son procédé de préparation et son utilisation pharmaceutique | |
| EP3502113A4 (fr) | Sel pharmaceutiquement acceptable d'inhibiteur d'egfr, forme cristalline de celui-ci, son procédé de préparation et son application | |
| EP3632907A4 (fr) | Dérivé de n-(azaaryl)cyclolactame-1-carboxamide, son procédé de préparation et son utilisation | |
| EP3508481A4 (fr) | Forme cristalline du chlorhydrate de l'ozanimod et son procédé de préparation | |
| EP3812378A4 (fr) | Formes cristallines de l'arn-509, procédé de préparation correspondant et utilisation associée | |
| IL283968A (en) | Benzamides of pyrazole-amino-pyrimidine type substances and their use | |
| EP3647312A4 (fr) | Forme cristalline d'azd9291 deutéré, procédé de préparation associé et utilisation correspondante | |
| EP4059926A4 (fr) | Forme cristalline de tafamidis ainsi que son procédé de préparation et son utilisation | |
| EP3502103A4 (fr) | Forme cristalline, type de sel d'un dérivé de 2-hydro-pyrazole substitué et son procédé de préparation | |
| EP3530650A4 (fr) | Forme cristalline de (r)-4-hydroxy-2-oxo-1-pyrrolidineacétamide, son procédé de préparation et son utilisation | |
| EP3677575A4 (fr) | Forme cristalline du chlorhydrate d'ozanimod et procédé de préparation correspondant | |
| EP3658278A4 (fr) | Métallophosphates cristallins, leur procédé de préparation et leur utilisation | |
| EP3272751A4 (fr) | Forme cristalline de l'ipi-145 et son procédé de préparation | |
| EP3569590A4 (fr) | Forme cristalline de (r)-4-hydroxy-2-oxo-1-pyrrolidineacétamide, son procédé de préparation et son application | |
| EP3466939A4 (fr) | Nouvelle forme cristalline de la dapagliflozine, son procédé de préparation et son utilisation | |
| EP3712155A4 (fr) | Forme cristalline d'un dérivé de sesquiterpène, procédé de préparation associé et utilisation correspondante | |
| EP3696168A4 (fr) | Procédé de préparation de 2-chloro-5-trifluorométhylpyridine | |
| EP3572399A4 (fr) | Forme cristalline de gft-505 et procédé de préparation et d'utilisation de celle-ci | |
| EP3545957A4 (fr) | Composition pharmaceutique de dérivés de la pyridone et son procédé de préparation | |
| GB201918401D0 (en) | Novel crystalline forms of Flufenacet, methods for their preparation and use of the same | |
| SG11202112354SA (en) | Crystal form of pyridone derivative, and preparation method and use thereof | |
| EP3733666A4 (fr) | Forme cristalline de di-p-toluènesulfonate de valbénazine, procédé de préparation associé et utilisation correspondante |